ADLARITY® is applied once per week1

Initiating Patients on ADLARITY

Application Site Flexibility

Important Reminders

Available in 5-mg and 10-mg strengths.1

One once-weekly ADLARITY transdermal system replaces 7 days of oral donepezil 5 mg/d or 10 mg/d tablets.1

Starting ADLARITY1

  • The recommended starting dose of ADLARITY is 5 mg/d
  • After 4 to 6 weeks, the dose may be increased to 10 mg/d

Switching to ADLARITY from oral donepezil1

  • Patients treated with oral donepezil 5 mg/d can be switched to ADLARITY 5 mg/d once weekly
  • If the patient has been on oral donepezil 5 mg/d for at least 4 to 6 weeks or on oral donepezil 10 mg/d, the patient may be switched immediately to ADLARITY 10 mg/d once weekly

ADLARITY is conveniently administered without regard to food intake.1

ADLARITY offers patients and caregivers application site flexibility1

Recommended application site

ADLARITY may be applied to the upper back below the shoulder blades (avoiding the spine), where it may be less likely to be removed by the patient, or the lower back.2

ADLARITY® may be applied to the back and upper buttocks.

Back and
upper buttocks

For patients who are able to self-apply or if ADLARITY is not expected to be removed by the patient before the full 7 days

ADLARITY may be easily self-applied on the upper buttocks or the upper outer thigh.2

ADLARITY® may be self-applied on the upper buttocks or the upper outer thigh.

Upper buttocks or the
upper outer thigh

ADLARITY should be replaced every 7 days. Only 1 transdermal system should be worn at a time.1

  • Remind patients to apply the transdermal system to clean, dry, intact, healthy skin with minimal hair

Work with the patient or caregiver to discuss and select a minimum of 3 application sites. The same application site must not be used for 14 days after removing a transdermal system from that site.1

See the Instructions for Use for step-by-step instructions.

Communicating important reminders about ADLARITY

  • ADLARITY is available in 2 dosage strengths: 5 mg/d and 10 mg/d1
  • Each ADLARITY transdermal system is applied for 7 days1
  • ADLARITY is packaged as 4 transdermal systems per 1 carton1
  • Each carton of ADLARITY contains 28 days of treatment1

NOTE: Samples of ADLARITY are packaged differently than what is dispensed in the pharmacy. Samples of ADLARITY 5 mg/d and ADLARITY 10 mg/d contain 1 transdermal system per carton (1 week of treatment).

One carton of ADLARITY® includes 4 transdermal systems, which equals 28 days of treatment.

1 carton = 4 transdermal systems = 28 days of treatment

Storage and temperature considerations1,3

  • ADLARITY use does not need to be interrupted due to bathing or hot weather and can be used at temperatures up to 108 ˚F. Instruct patients or caregivers to avoid long exposure to external heat sources (excessive sunlight, saunas, solariums, or heating pads)

Store ADLARITY in the refrigerator.1
Prior to application, allow the pouch to reach room temperature before opening. Use the ADLARITY transdermal system within 24 hours of removing from the refrigerator.1

Missed dose1

  • Apply a new transdermal system immediately and replace the new transdermal system 7 days later at the usual application time to start a new cycle
  • Instruct patients and caregivers not to apply 2 transdermal systems to make up for a missed application

INDICATION

ADLARITY is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type.

IMPORTANT SAFETY INFORMATION

Contraindications

ADLARITY is contraindicated in patients with known hypersensitivity to donepezil or to piperidine derivatives or with a history of allergic dermatitis with use of ADLARITY.

INDICATION

ADLARITY is indicated for the treatment of mild, moderate, and severe dementia of the Alzheimer's type.

IMPORTANT SAFETY INFORMATION

Contraindications

ADLARITY is contraindicated in patients with known hypersensitivity to donepezil or to piperidine derivatives or with a history of allergic dermatitis with use of ADLARITY.

Warnings and Precautions
  • Application site skin reactions: ADLARITY may cause skin application-site reactions. These reactions are not necessarily indicative of sensitization; however, allergic contact dermatitis may occur and should be suspected if application-site reactions spread beyond the size of the transdermal system, there is evidence of a more intense local reaction, and symptoms do not significantly improve within 48 hours of transdermal system removal.
  • Anesthesia: ADLARITY, as a cholinesterase inhibitor, is likely to exaggerate succinylcholine-type muscle relaxation during anesthesia.
  • Cardiovascular conditions: Cholinesterase inhibitors, including ADLARITY, may have vagotonic effects on the sinoatrial and atrioventricular nodes. These effects may manifest as bradycardia or heart block in patients both with and without known underlying cardiac conduction abnormalities. Syncopal episodes have been reported in association with the use of donepezil.
  • Nausea and vomiting: Donepezil, the active ingredient in ADLARITY, may cause diarrhea, nausea, and vomiting. In most cases these effects have been transient, although some cases lasted 1 to 3 weeks. Patients should be monitored closely during initiation of treatment and after dose increases.
  • Peptic ulcer disease and gastrointestinal bleeding: Cholinesterase inhibitors, including ADLARITY, may increase gastric acid secretion. Patients should be monitored closely for active or occult gastrointestinal bleeding, especially those with a history of ulcer disease or those receiving concurrent nonsteroidal anti-inflammatory drugs (NSAIDs).
  • Genitourinary conditions: Although not observed in clinical trials of ADLARITY, bladder outflow obstruction may occur.
  • Seizures: Cholinomimetics, including ADLARITY, are believed to have some potential to cause generalized convulsions; however, seizure activity may also be a manifestation of Alzheimer's disease.
  • Pulmonary conditions: Cholinesterase inhibitors, including ADLARITY, should be prescribed with care to patients with a history of asthma or obstructive pulmonary disease.
Adverse Reactions

The most common adverse reactions (greater than 5% with donepezil tablets and twice the placebo rate) are nausea, diarrhea, insomnia, vomiting, muscle cramps, fatigue, and anorexia.

Drug Interactions

Cholinesterase inhibitors, including donepezil, have the potential to interfere with the activity of anticholinergic medications. A synergistic effect may be expected when cholinesterase inhibitors are given concurrently with succinylcholine, similar neuromuscular blocking agents, or cholinergic agonists such as bethanechol.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/MedWatch or call 1‑800‑FDA‑1088. Please click here for Full Prescribing Information.

References: 1. ADLARITY. Prescribing information. Corium, LLC; 2022. 2. ADLARITY. Instructions for use. Corium, LLC; 2022. 3. Data on file. Corium, LLC.